Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04488393 · ClinicalTrials.gov registry record
Clinical Performance of NIPT in Multiple Gestation Pregnancies
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 2,000
- Enrollment target
NCT04488393: Completed study, sponsored by University of Pennsylvania.
NCT04488393 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 2,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04488393 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 2,000 participants
- Enrollment target
Study Summary
This study plans to evaluate the clinical performance of the MaterniT21 PLUS and/or GENOME Laboratory Developed Test, in the detection of fetal trisomy 21 in circulating cell-free DNA extracted from maternal blood samples obtained from women pregnant with a twin gestation.
Interventions
- DEVICE MaterniT21 PLUS and GENOME Laboratory-Developed Tests
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2020-03-01 |
| Est. Completion | 2022-06-19 |
What the finished NCT04488393 record still lists
NCT04488393 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which MaterniT21 PLUS and GENOME Laboratory-Developed Tests is the first listed.
NCT04488393 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04488393 about?
NCT04488393 is a clinical study titled "Clinical Performance of NIPT in Multiple Gestation Pregnancies". This study plans to evaluate the clinical performance of the MaterniT21 PLUS and/or GENOME Laboratory Developed Test, in the detection of fetal trisomy 21 in circulating cell-free DNA extracted from maternal blood samples obtained from women pregnant with a twin gestation.
What is the current status of trial NCT04488393?
This trial is currently completed. The enrollment target is 2,000 participants. The study started on 2020-03-01. Estimated completion is 2022-06-19.
What interventions are being tested in trial NCT04488393?
The interventions under investigation include: MaterniT21 PLUS and GENOME Laboratory-Developed Tests (DEVICE).
Who is sponsoring clinical trial NCT04488393?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI